Fgfr4 - fibroblast growth factor receptor 4 Gene

Rattus norvegicus

Gene ID: 25114 | Gene type: protein coding

About Fgfr4

Primary_assembly 17: 9,461,547-9,476,242 reverse strand.mRatBN7.2:CM026990.1

This gene has 3 transcripts (splice variants), 122 orthologues, 54 paralogues and is associated with 23 phenotypes. Biased expression in Lung (RPKM 84.6), Kidney (RPKM 61.7) and 4 other tissues.

Summary

Predicted to enable Fibroblast Growth Factor binding activity; fibroblast growth factor-activated receptor activity; and heparin binding activity. Acts upstream of or within Fibroblast Growth Factor receptor signaling pathway. Predicted to be located in several cellular components, including Golgi apparatus; endoplasmic reticulum; and transport vesicle. Predicted to be part of receptor complex. Predicted to be integral component of plasma membrane. Predicted to colocalize with cell-cell junction. Human ortholog(s) of this gene implicated in carcinoma (multiple); liver cirrhosis; prostate cancer; and stomach Cancer. Orthologous to human FGFR4 (Fibroblast Growth Factor receptor 4). [provided by Alliance of Genome Resources, Apr 2022]

Fgfr4 Products(1)

mRNA	Protein	Name
NM_001109904.1	NP_001103374.1	fibroblast growth factor receptor 4 precursor

Fgfr4 Protein Structure

Ig_3

PKc_like

0
200
400
600
801 a.a.

Protein Preferred Names

Protein Names

fibroblast growth factor receptor 4

FGFR-4

Recombinant Fgfr4 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P73061	FGFR-4 Protein, Rat (HEK293, Fc, Solution)	Q498D6 (F17-D367)	≥95%
HY-P75190	FGFR-4 Protein, Rat (HEK293, His)	Q498D6 (M1-D367)	≥95%

Related Agents

Approval

Bioactive Molecules (7)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10981	Lenvatinib	Inhibitor	99.84%	Yes
HY-18708	Erdafitinib	Inhibitor	99.66%	Unkown
HY-13311	Infigratinib	Inhibitor	99.72%	Yes
HY-109099	Pemigatinib	Inhibitor	99.73%	Yes
HY-100818	Futibatinib	Inhibitor	99.65%	Unkown
HY-10981A	Lenvatinib mesylate	Inhibitor	99.86%	Yes
HY-13311A	Infigratinib phosphate	Inhibitor	99.74%	Yes

Clinical Phase

Bioactive Molecules (10)

Cat. No.	Product Name	Effect	Purity	Phase
HY-13330	Fexagratinib	Inhibitor	99.85%	Phase 3
HY-100019	Rogaratinib	Inhibitor	99.86%	Phase 3
HY-100492	Fisogatinib	Inhibitor	99.87%	Phase 2
HY-101568	Roblitinib	Inhibitor	99.74%	Phase 2
HY-19957	Zoligratinib	Inhibitor	99.76%	Phase 2
HY-101466A	E7090 succinate	Inhibitor	99.17%	Phase 2
HY-13304	LY2874455	Inhibitor	98.03%	Phase 1
HY-119367	ODM-203	Inhibitor	99.91%	Phase 1
HY-19983	ASP5878	Inhibitor	99.86%	Phase 1
HY-101768	PRN1371	Inhibitor	99.43%	Phase 1

Pre-clinical Phase

Bioactive Molecules (24)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-12823	BLU9931	Inhibitor	99.95%	Unkown
HY-15599	SSR128129E	Inhibitor	99.85%	Unkown
HY-18602	FIIN-2	Inhibitor	99.63%	Unkown
HY-101466	E7090	Inhibitor	99.64%	Unkown
HY-15813	FIIN-1	Inhibitor	99.11%	Unkown
HY-100631	FGFR4-IN-1	Inhibitor	99.89%	Unkown
HY-100491	H3B-6527	Inhibitor	≥98.0%	Unkown
HY-18603	FIIN-3	Inhibitor	99.66%	Unkown
HY-131704	FGFR4-IN-5	Inhibitor	98.03%	Unkown
HY-147515	FGFR4-IN-11	Inhibitor	/	Unkown
HY-129181	FGFR4-IN-4	Inhibitor	/	Unkown
HY-152104	FGFR-IN-9	Inhibitor	/	Unkown
HY-142921	FGFR-IN-2	Inhibitor	/	Unkown
HY-151903S	FGFR2/3-IN-1	Inhibitor	/	Unkown
HY-144759	FGFR4-IN-9	Inhibitor	/	Unkown
HY-158248	FGFR4-IN-19	Inhibitor	/	Unkown
HY-147715	FGFR3-IN-3	Inhibitor	/	Unkown
HY-152146	HDAC-IN-50	Inhibitor	/	Unkown
HY-160621	CXF-009	Inhibitor	/	Unkown
HY-146541	FGFR4-IN-10	Inhibitor	/	Unkown
HY-161326	CXF-007	Inhibitor	/	Unkown
HY-150652	FGFR-IN-8	Inhibitor	/	Unkown
HY-155028	FGFR-IN-11	Inhibitor	/	Unkown
HY-15599A	SSR128129E free acid	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Fgfr4	NCBI	NCBI:2264

Name
Email *

	Sorry, but the email address you supplied was invalid.